Acceleron and Celgene announce interim clinical data for sotatercept

24-04-2014 Business Wire HealthComments (0)

Acceleron PharmaBiotechnologyCelgene Corp.HematologyUSA

Acceleron Pharma (XLRN) and Celgene (CELG) presented interim data for sotatercept demonstrating dose dependent increases in hemoglobin in patients with end stage renal disease (ESRD) on hemodialysis

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top